GPCM
RUBY

Granite Point Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Granite Point Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-36,848
Closed -$667K – 119
2019
Q1 		$667K Hold
36,848
– – 0.06% 79
2018
Q4 		$593K Sell
36,848
-81,852
-69% -$1.49M 0.12% 67
2018
Q3 		$2.85M Buy
+118,700
New +$2.71M 0.19% 48

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Granite Point Capital Management's RUBY Position: Q2 2019 in Review

Granite Point Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2019, closing a stake of 36,848 shares — an estimated $667K sold.

Granite Point Capital Management first reported a position in RUBY in Q3 2018 and held it in 3 quarters. The position peaked at $2.85M in Q3 2018. 69 funds tracked by Wall St. Rank hold RUBY as of Q2 2019.

  • Granite Point Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Granite Point Capital Management sold 36,848 Rubius Therapeutics, Inc shares in Q2 2019, an estimated $667K.
  • Granite Point Capital Management first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 3 quarters.
  • Granite Point Capital Management's Rubius Therapeutics, Inc position peaked at $2.85M in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2019.

Based on Granite Point Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.